Photosensitive porphyrinic Zr-MOF (PCN-224) was used to load Food and Drug Administration (FDA)-approved vascular endothelial growth factor receptor 2 (VEGFR2) inhibitor Apatinib, followed by the coating of MnO2 shell and cell membrane extracted from mouse breast cancer cell line 4T1 layer, in turn, to develop the core-shell nanocomposite aMMTm with an excellent encapsulation efficiency of >98.3% for Apatinib. The gene discussed is KDR; the disease is breast carcinoma.